Synaptic dysfunction represents one of the earliest pathological events in neurodegenerative diseases, preceding overt neuronal loss and clinical symptom onset by years or even decades. Synapses — the specialized junctions between [neurons[/entities/neurons that enable chemical and electrical signal transmission — are exquisitely sensitive to perturbations in protein homeostasis, energy metabolism, and inflammatory signaling. In [Alzheimer's disease[/diseases/alzheimers, synaptic loss is the strongest pathological correlate of cognitive decline, surpassing even [amyloid-beta[/entities/amyloid-beta plaque burden or [neurofibrillary tangle] density [1]. Across the spectrum of neurodegenerative conditions — including [Parkinson's disease[/diseases/parkinsons, [Huntington's disease[/mechanisms/huntington-pathway, [amyotrophic lateral sclerosis (ALS)[/diseases/als, and [Frontotemporal Dementia (FTD)[/diseases/ftd — disrupted synaptic signaling is a convergent pathological feature that bridges diverse upstream etiologies to shared downstream consequences of circuit dysfunction and cognitive or motor impairment.
The human brain contains approximately 100 trillion synapses, each requiring precise coordination of hundreds of proteins for neurotransmitter release, receptor activation, and synaptic plasticity [2]. This molecular complexity renders synapses vulnerable to disruption by misfolded proteins, mitochondrial dysfunction, [neuroinflammation[/mechanisms/neuroinflammation, and impaired [autophagy[/entities/autophagy. Understanding synaptic dysfunction is critical not only for elucidating disease mechanisms but also for developing biomarker-based early detection strategies and synapse-protective therapeutics.
The following diagram illustrates how pathological proteins converge on synaptic targets to disrupt neurotransmission:
The presynaptic terminal is a highly specialized compartment that must maintain pools of synaptic vesicles, ensure efficient neurotransmitter loading, and execute calcium-dependent exocytosis with millisecond precision. Pathological proteins disrupt multiple aspects of this machinery.
[Amyloid-Beta[/entities/amyloid-beta at the presynaptic terminal: Soluble [amyloid-beta[/entities/amyloid-beta oligomers bind to presynaptic terminals and impair neurotransmitter release before plaque formation occurs. [Aβ[/entities/amyloid-beta oligomers interact with synaptic vesicle protein 2A (SV2A), SNAP-25, and synaptotagmin, disrupting vesicle docking and fusion [3]. In transgenic mouse models of [Alzheimer's disease[/diseases/alzheimers, presynaptic bouton loss precedes postsynaptic dendritic spine retraction, suggesting that presynaptic dysfunction may be the initiating event.
[alpha-synuclein[/mechanisms/alpha-synuclein and vesicle dynamics: [alpha-synuclein[/proteins/alpha-synuclein normally localizes to presynaptic terminals, where it associates with synaptic vesicle membranes and promotes SNARE complex assembly for vesicle fusion [4]. In [Parkinson's disease[/diseases/parkinsons and [Lewy body dementia[/diseases/lewy-body-dementia, pathological [alpha-synuclein[/proteins/alpha-synuclein aggregates sequester synaptic vesicle proteins, reduce the recycling vesicle pool, and impair [dopamine[/entities/dopamine release from nigrostriatal terminals. This presynaptic dysfunction in [dopaminergic neurons[/cell-types/dopaminergic-neurons-snpc of the [substantia nigra[/brain-regions/substantia-nigra produces the characteristic motor symptoms of parkinsonism.
[TDP-43[/entities/tdp-43 and synaptic RNA metabolism: [TDP-43[/entities/tdp-43 normally shuttles between the nucleus and cytoplasm, regulating mRNA processing for numerous synaptic proteins. In [ALS[/diseases/als and [FTD[/diseases/ftd, cytoplasmic [TDP-43[/proteins/tdp-43 aggregation leads to dysregulated mRNA transport to synapses, reducing local translation of critical presynaptic components [5].
The postsynaptic density (PSD) is a complex signaling platform containing hundreds of proteins that transduce neurotransmitter signals into intracellular responses. Disease-associated proteins directly disrupt this machinery.
[NMDA receptor[/entities/nmda-receptor receptor dysfunction: [amyloid-beta[/entities/amyloid-beta oligomers bind to or near [NMDA receptor[/entities/nmda-receptor receptors], triggering aberrant calcium influx through extrasynaptic GluN2B-containing receptors. This activates calcineurin-mediated dephosphorylation cascades, leading to [AMPA receptor[/proteins/ampa-receptor internalization and long-term depression (LTD) of synaptic transmission [6]. The imbalance between [long-term potentiation (LTP)[/mechanisms/long-term-potentiation and LTD is a hallmark of early Alzheimer's pathology.
[Tau[/entities/tau-protein(/proteins/tau-protein) mislocalization to dendrites: Under pathological conditions, hyperphosphorylated tau] relocates from axons to the somatodendritic compartment, where it disrupts postsynaptic signaling. Dendritic tau interacts with the Src kinase Fyn, which phosphorylates GluN2B subunits of [NMDA receptor[/entities/nmda-receptor receptors, enhancing [excitotoxicity[/entities/excitotoxicity [7]. Reducing Fyn-tau interactions has emerged as a therapeutic strategy for Alzheimer's Disease.
PSD-95 and scaffold protein loss: The scaffold protein PSD-95 anchors glutamate receptors and signaling molecules at the postsynaptic density. CSF levels of PSD-95 are elevated in [Alzheimer's disease[/diseases/alzheimers patients, reflecting its release from degenerating synapses [8]. Loss of PSD-95 correlates with cognitive decline and is detectable in the earliest stages of disease.
Synapses are among the most energy-demanding structures in the body, consuming approximately 70% of neuronal ATP for maintaining ion gradients, vesicle recycling, and receptor trafficking. Synaptic [mitochondria[/entities/mitochondrial-dynamics are particularly vulnerable to damage because they operate far from the cell body, where most mitochondrial biogenesis occurs.
In [Alzheimer's disease[/diseases/alzheimers, [Aβ[/entities/amyloid-beta accumulates within synaptic mitochondria and inhibits complex IV of the electron transport chain, reducing ATP production by 25–50% in affected synapses [9]. The resulting energy deficit impairs calcium buffering, vesicle recycling, and receptor trafficking. [DRP1[/entities/drp1-mediated mitochondrial fragmentation is enhanced at synapses in multiple neurodegenerative diseases, producing small, dysfunctional organelles that generate excessive [reactive oxygen species (ROS)[/entities/ros [10].
[LTP[/entities/long-term-potentiation — the activity-dependent strengthening of synaptic transmission — is the cellular basis of learning and memory. Inhibition of [LTP[/entities/long-term-potentiation is one of the earliest functional deficits in animal models of neurodegeneration.
In Alzheimer's Disease models, soluble Aβ oligomers block [LTP[/entities/long-term-potentiation induction in hippocampal CA1 [neurons[/entities/neurons at picomolar concentrations, well below those required for neurotoxicity [11]. This occurs through activation of [calcineurin[/genes/calcineurin, inhibition of CaMKII, and impaired AMPA receptor surface expression. Remarkably, anti-Aβ antibodies such as [lecanemab[/treatments/lecanemab and [donanemab[/treatments/donanemab can rescue [LTP[/entities/long-term-potentiation deficits in vitro, providing a mechanistic rationale for immunotherapy approaches.
Neurodegenerative diseases frequently disrupt the balance between excitatory and inhibitory synaptic transmission, leading to network hyperexcitability. In Alzheimer's Disease, loss of GABAergic interneurons — particularly [parvalbumin-positive (PV+) interneurons[/cell-types/pv-interneurons and [somatostatin-positive (SST+) interneurons[/cell-types/sst-interneurons — reduces inhibitory tone in cortical and hippocampal circuits [12]. This E/I imbalance contributes to network hypersynchrony, subclinical epileptiform activity, and accelerated cognitive decline. Approximately 22% of Alzheimer's patients exhibit subclinical epileptiform activity on EEG, and seizure history is associated with earlier symptom onset.
In [Huntington's disease[/mechanisms/huntington-pathway, loss of [medium spiny neurons[/cell-types/medium-spiny-neurons in the [striatum[/brain-regions/striatum disrupts cortico-basal ganglia circuit dynamics, producing chorea and other movement abnormalities through disinhibition of thalamocortical projections.
A groundbreaking discovery has linked the innate immune [complement system[/entities/complement-system to pathological synapse loss in neurodegeneration. During normal brain development, complement proteins C1q and C3 tag weak or redundant synapses for elimination by [microglia[/cell-types/microglia/entities/microglia, a process called synaptic pruning [13]. In neurodegenerative diseases, this developmental program is aberrantly reactivated.
In Alzheimer's Disease, [C1q[/proteins/complement-c1q is dramatically upregulated (300-fold) at synapses surrounding amyloid plaques. C1q binds to exposed phosphatidylserine on stressed synapses, activating the classical complement cascade (C1q → C4 → C2 → C3). C3-tagged synapses are then engulfed by [microglia[/entities/microglia and by 45–55% in moderate AD [1]. The temporal progression follows the Braak staging of tau pathology]: entorhinal [cortex[/brain-regions/cortex → [hippocampus[/brain-regions/hippocampus → association cortices → primary cortices.
The "amyloid cascade" triggers synaptic dysfunction through multiple parallel pathways: direct Aβ oligomer toxicity at synapses, tau-mediated postsynaptic disruption, complement-mediated elimination, and astrocyte-mediated synaptotoxicity via reactive [astrocytes[/cell-types/astrocytes releasing saturated fatty acids.
In [Parkinson's disease[/diseases/parkinsons, synaptic dysfunction at dopaminergic terminals in the [striatum[/brain-regions/striatum precedes frank neuronal loss by years. [alpha-synuclein[/proteins/alpha-synuclein pathology begins at presynaptic terminals, where it disrupts vesicle docking, reduces dopamine release, and impairs dopamine reuptake by the dopamine transporter (DAT) [16]. Dopamine imaging with DaTscan reveals 50–70% loss of striatal dopaminergic innervation at the time of motor symptom onset, indicating years of preceding synaptic dysfunction.
At the [neuromuscular junction] in [ALS[/diseases/als, synaptic dysfunction manifests as denervation of motor endplates, reduced quantal content of [acetylcholine[/entities/acetylcholine release, and compensatory sprouting of remaining motor [neurons[/entities/neurons. This "dying-back" pattern of degeneration begins at distal synapses and progresses proximally toward motor neuron cell bodies in the [spinal cord[/brain-regions/spinal-cord [17].
The identification of fluid biomarkers that reflect synaptic integrity has transformed early disease detection and therapeutic monitoring.
| Biomarker | Type | Compartment | Changes in AD | Clinical Utility |
|---|---|---|---|---|
| Neurogranin | Postsynaptic | CSF | ↑ 40–60% | Early AD detection, correlates with cognitive decline |
| SNAP-25 | Presynaptic | CSF | ↑ 30–50% | Predicts cognitive decline, synapse degeneration marker |
| Synaptotagmin-1 | Presynaptic | CSF | ↑ 20–40% | Tracks synaptic vesicle loss |
| GAP-43 | Presynaptic | CSF | ↑ 35–55% | Growth-associated, reflects synaptic remodeling |
| PSD-95 | Postsynaptic | CSF | ↑ 25–45% | Reflects postsynaptic density disruption |
CSF neurogranin levels are elevated even in preclinical AD (amyloid-positive, cognitively normal individuals), making it one of the earliest detectable biomarkers [18]. Importantly, changes in synaptic protein levels in CSF precede changes in [neurofilament light (NfL)], suggesting that synaptic dysfunction occurs before neurodegeneration [19].
Synaptic vesicle glycoprotein 2A (SV2A) PET imaging using [¹¹C]UCB-J has enabled in vivo quantification of synaptic density. Studies in Alzheimer's Disease demonstrate 20–40% reductions in SV2A binding in the [hippocampus[/brain-regions/hippocampus and [entorhinal cortex[/brain-regions/entorhinal-cortex in early-stage disease [20]. SV2A PET is now being incorporated into clinical trials as a pharmacodynamic endpoint for synapse-protective therapies.
Several therapeutic strategies aim to protect or restore synaptic function in neurodegeneration:
Anti-amyloid immunotherapy: [Lecanemab[/treatments/lecanemab and [donanemab[/treatments/donanemab reduce Aβ burden and slow cognitive decline, partly through synapse protection. SV2A PET sub-studies show that Aβ removal attenuates synaptic loss.
Complement inhibition: Anti-C1q antibodies (e.g., ANX005) and C3 inhibitors are in clinical trials for Alzheimer's and Huntington's diseases, aiming to prevent complement-mediated synapse elimination.
[NMDA receptor[/entities/nmda-receptor receptor] modulation: [Memantine[/treatments/memantine, an approved Alzheimer's therapy, is a low-affinity [NMDA receptor[/entities/nmda-receptor[/entities/nmda-receptor receptor antagonist that blocks pathological extrasynaptic receptor activation while preserving physiological synaptic NMDA signaling.
Neurotrophic factor enhancement: [BDNF[/entities/bdnf and [GDNF[/entities/gdnf support synaptic maintenance, and strategies to enhance their signaling — including small-molecule TrkB agonists and gene therapy — are under investigation.
Sigma-2 receptor modulators: CT1812, a sigma-2 receptor antagonist, displaces Aβ oligomers from synapses and is in Phase 2 trials for Alzheimer's Disease. Early results show normalization of CSF synaptic biomarkers [21].
Optogenetic and chemogenetic circuit restoration: Preclinical studies using [optogenetics[/technologies/optogenetics have demonstrated that restoring specific circuit activity can rescue cognitive function even in the presence of amyloid and tau pathology, suggesting that synaptic dysfunction is potentially reversible [22].
Epigenetic modulation: [HDAC inhibitors[/treatments/hdac-inhibitors enhance expression of synaptic plasticity genes and have shown promise in restoring LTP and memory in AD mouse models.
Extracellular vesicle therapies: [Exosomes[/entities/exosomes derived from mesenchymal stem cells carry neuroprotective factors that enhance synaptic plasticity and reduce inflammation.
The study of Synaptic Dysfunction In Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This review summarizes: (1) Aβ-dependent mechanisms of synaptic dysfunction including impaired SV recycling, AMPA/NMDA receptor endocytosis, and PSD-95 loss; (2) LOAD genetic risk factors (APOE4, ABCA7, BIN1, CD2AP, PICALM, SORL1, EPH1A) and their roles in synaptic trafficking; (3) Evidence that earliest synaptic dysfunctions in eFAD are triggered by Aβ while LOAD may involve direct synaptic disruption by trafficking genes
Model System: Review paper - synthesizes findings from multiple model systems including mouse models (5xFAD, APP/PS1, 3xTg-AD, APOE4 knock-in mice), iPSC neurons, and human postmortem brain tissue
Statistical Significance: Not applicable - review paper
Catarina Perdigão et al., (2020)
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 0 references |
| Replication | 100% |
| Effect Sizes | 50% |
| Contradicting Evidence | 100% |
| Mechanistic Completeness | 50% |
Overall Confidence: 53%